Purpose

This study is an international, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF), which is designed to collect safety and performance data on commercially available Perform® Fracture. Data collected from this study will be used for purposes, including but not limited to, PMS, peer-reviewed publications, education materials, future regulatory submissions, and/or product development.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18 years or older at the time of the informed consent or the non-opposition (when applicable) - Informed and willing to sign an informed consent form (ICF) approved by IRB or EC (when applicable) - Willing and able to comply with the requirements of the study protocol - Considered a candidate for shoulder arthroplasty with the device for shoulder joint disabled by: - Traumatic or pathologic conditions of the shoulder resulting in fracture of the glenohumeral joint, including humeral head fracture and displaced 3-or 4-part proximal humeral fractures - Fracture sequelae - Revisions where adequate fixation can be achieved, and adequate bone stock remains after final reconstruction - Proximal humerus bone defect (reverse configuration)

Exclusion Criteria

  • Not able to comply with the study procedures based on the judgment of the assessor (e.g., cannot comprehend study questions, inability to keep scheduled assessment times) - Patient belongs to a vulnerable group of subjects, including minor subjects, those unable to decide for themselves to participate or needing a LAR, or others who could be subject to coercion (subjects who may not be acting on their own initiative) (referred as "vulnerable subject" in the section 3.44 of the ISO 14155:2011 norm) - Any absolute contraindications as mentioned in the device Instruction For Use (available on ifu.stryker.com)

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Tornier Perform® Humeral System - Fracture Commercially available convertible humeral system for anatomic and reverse shoulder arthroplasty.
  • Device: Tornier Perform® Humeral System - Fracture
    A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty. A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.

Recruiting Locations

More Foundation
Phoenix, Arizona 85023
Contact:
Leesa Maczko
623-241-8639
Leesa.Maczko@more-foundation.org

University of Arkansas Medical Sciences
Little Rock, Arkansas 72205
Contact:
Dana Garrison
501-231-1193
dlgarrison@uams.edu

Eisenhower Health Desert Orthopedic Center
Rancho Mirage, California 92270
Contact:
Lainie Hughes
760-837-8237
LHughes@eisenhowerhealth.org

California Pacific Orthopaedics
San Francisco, California 94118
Contact:
Katie Sisson
ksisson@calpacortho.com

Washington University
Saint Louis, Missouri 63110
Contact:
Julianne Sefko
314-747-2496
jsefko@wustl.edu

Tennessee Orthopaedic Alliance
Columbia, Tennessee 38401
Contact:
Asha Phillips
615-329-6600
phillipsad@toa.com

University of Texas/UT Health
Houston, Texas 77030
Contact:
Layla Haidar
713-962-9954
Layla.Haidar@uth.tmc.edu

More Details

NCT ID
NCT05773352
Status
Recruiting
Sponsor
Stryker Trauma GmbH

Study Contact

Monica Fleeman
251-465-5969
monica.fleeman@stryker.com

Detailed Description

This is an International, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available Perform® Fracture shoulder system in both the anatomic and reversed configurations. The primary endpoint of this study is to demonstrate decreased pain and improved subjects' shoulder functionality of daily living by achieving a mean of American Shoulder and Elbow Surgeons (ASES) shoulder score higher than 62 points, at 2-year follow-up post-operatively, regardless of configuration (anatomic or reverse). Retrospective inclusions are allowed: preoperative and intra operative data can be collected retrospectively up to 2 months after the surgery date. Secondary outcome measures include patient reported outcome measures (PROMs) and standard radiographic findings, including, but not limited to: bone erosion, device migration/subsidence, component breakage, radiolucency, and ossification. Safety and performance data will be collected at surgery, immediate post-op, and up to 10 years post-operation. Patient Reported Outcome Measures (PROMs), device revision and Adverse Events (AEs) will be assessed annually throughout the study. Range of Motion (ROM), strength and radiographic imaging assessments of the study shoulder will also be performed for in-person milestones visits at 6 months (radiographic imaging assessments), 1-, 2-, 5- and 10-year, post-operatively.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.